Find information on thousands of medical conditions and prescription drugs.

Orlistat

Orlistat (marketed as Xenical by Roche) is a drug designed to treat obesity. Its primary function is to prevent the absorption of dietary fats, thereby reducing caloric intake. It is intended for use in conjunction with a physician-supervised reduced calorie diet. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
Methoxsalen
OCL
Octabenzone
Octanoic acid
Octopamine
Octreotide
Ofloxacin
Ofloxacin
Olanzapine
Omeprazole
Oncovin
Ondansetron
Opium
Oratane
Oretic
Orinase
Orlistat
Ornidazole
Ornithine
Orotic acid
Orphenadrine
Ortho Evra
Oruvail
Ovcon
Ovral
Ovrette
Oxaliplatin
Oxamniquine
Oxandrin
Oxandrolone
Oxaprozin
Oxazepam
Oxcarbazepine
Oxetine
Oxibendazole
Oxiracetam
Oxprenolol
Oxybenzone
Oxybuprocaine
Oxycodone
Oxycodone
Oxymetazoline
Oxymetholone
Oxymorphone
Oxytetracycline
Oxytocin
P
Q
R
S
T
U
V
W
X
Y
Z

Pharmacology

Orlistat works by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested. Only trace amounts of orlistat are absorbed systemically, the primary effect is local lipase inhibition within the GI tract after an oral dose. The primary route of elimination is through the feces.

At the standard prescription dose of 120 mg three times daily before meals, orlistat prevents approximately 30% of dietary fat from being absorbed.

Efficacy

The amount of weight loss achieved with orlistat is variable. In 1 year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass. Between 16.4% and 24.8% achieved at least a 10% decrease in body mass. A significant amount of subjects regained the weight after they stopped using orlistat. Despite this cosmetically small effect, there was a 37% reduction in the incidence of Type 2 diabetes, a significant difference.

Side effects

The primary side effects of the drug are GI-related. Side effects were most severe within the first year of therapy. Because its main effect is to prevent dietary fat from being absorbed, the fat is excreted unchanged in the feces and so the stool may become oily or loose. Increased flatulence is also common. Bowel movements may become frequent or urgent. Rare occurrence of fecal incontinence have been seen in clinical trials. To minimize these effects, foods with high fat content should be avoided.

The absorption of fat-soluble vitamins are inhibited by the use of orlistat. A multivitamin tablet containing these vitamins (D, E, A and beta-carotene) should be taken once a day, at least 2 hours before or after taking the drug.

Contraindications

Xenical is contraindicated in:

  • Malabsorption
  • Reduced gallbladder function (e.g. after cholecystectomy)
  • Pregnancy and breastfeeding
  • Certain kidney problems

Availability

In most areas orlistat is available by prescription only. In 2004, a lower-dose version of the drug (60 mg compared to 120 mg for the prescription version) was released over the counter in Australia and New Zealand; the United States is expected to follow in the near future.

On January 23, 2006, a US Food and Drug Administration advisory panel voted 11 to 3 to recommend the approval of an OTC formulation of orlistat (planned to be marketed under the name "Alli" by GlaxoSmithKline). The proposed product will consist of 60 mg dosage units, similar to the OTC products available elsewhere.

Read more at Wikipedia.org


[List your site here Free!]


Orlistat improves endothelial functioning - Nutrition and Cardiovascular Disease
From Nutrition Research Newsletter, 6/1/03

Endothelial dysfunction (ED) is an impairment of endothelium-dependent vasorelaxation due to a loss of nitric oxide (NO) bioactivity in the vessel wall. it is considered an early functional change preceding atherosclerosis. Obesity is also associated with ED, however, the exact cause of ED in obesity is unknown. The effect of weight loss on endothelium-dependent and -independent vasodilatory responses has not been studied. Orlistat, a lipase inhibitor that prevents fat absorption and prevents weight loss, also lowers LDL cholesterol more than expected from weight loss alone. This fact may be beneficial for vascular function because lowering of LDL cholesterol with statins improves endothelial function.

Recently, investigators compared the effects of moderate weight loss with or without simultaneous lowering of fat absorption and LDL cholesterol on endothelial function in obese women. This investigator-initiated, double-blind, placebo-controlled study was designed to achieve an 8% body weight loss both in a group of women receiving orlistat and in another group receiving placebo. The subjects had to fulfill the following inclusion criteria: 1) previous gestational diabetes mellitus; 2) current age 20 to 50 years; 3) current BMI between 28 and 35 kg/[m.sup.2]; and 4) no known acute or chronic disease. A total of 57 women fulfilled the criteria and participated in the following tests before and after weight loss: 1) assessment of in vivo endothelial function; 2) measurement of forearm composition by magnetic resonance imaging (MRI); and 3) measurement of circulating markers of glucose and lipid metabolism.

After baseline testing, the subjects were randomized to receive either orlistat 120 mg three times daily or an identical looking placebo, both in addition to the prescribed hypocaloric diet. Following an 8% body weight reduction, subjects were placed on a weight-maintaining diet for at least two weeks before baseline measurements were collected. A total of 47 women achieved the weight loss goal and completed the study.

Vascular function was assessed in forearm resistance vessels by measuring forearm blood flow responses to intrabrachial artery infusions of endothelium-dependent (acetylcholine [Ach]) and -independent (sodium nitorprusside [SNP]) vasodilators.

The desired weight loss was achieved in both groups. Forearm and body compositions changed similarly in both groups. Responses to Ach increased by 41% to the low dose (5.9 [+ or -] 0.6 versus 8.3 4 [+ or -] 0.3 for flow in the experimental/ control arm, P lesser than 0.01) and by 33% to the high dose (7.6 4 [+ or -] 0.8 versus 10.1 [+ or -] 0.6, P lesser than 0.001) ion the orlistat group, but they remained unchanged in the placebo group. The blood flow responses to SNP did not differ significantly between the groups. LDL cholesterol decreased significantly in the orlistat group from 3.5 4. [+ or -] 0.2 to 3.0 [+ or -] 0.1 mmol/l (P lesser than 0.01) but remained unchanged in the placebo group. Within the orlistat group, the decrease in LDL cholesterol correlated significantly with the improvement in the blood flow response to Ach (r = -044, P lesser than 0.05).

Investigators conclude that orlistat, but not moderate weight loss alone, improves endothelial function in women with previous gestational diabetes. This observed improvement is also associated with a lowering of LDL cholesterol by orlistat.

R. Bergholm, M. Tiikkainen, S. Vehkavaara, et al. Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilation in obese women with previous gestational diabetes, Diabetes Care, (26:1667-1672, June, 2003). Correspondence: Hannele Yki-Jarvinen, MD, FRCP, PhD, Department of Medicine, Division of Diabetes, University of Helsinki, PO Box 340, FIN-00029 HUCH, Helsinki, Finland. E-mail: ykijarvi@helsinki.fi

COPYRIGHT 2003 Frost & Sullivan
COPYRIGHT 2003 Gale Group

Return to Orlistat
Home Contact Resources Exchange Links ebay